Home > Rheumatology > ACR 2019 > Spotlight on Rheumatoid Arthritis > Cancer Treatment with Checkpoint Inhibitors in Ra Patients?

Cancer Treatment with Checkpoint Inhibitors in Ra Patients?

Presented By
Dr Sabina Sandigursky, New York University Langone Medical Center, USA
Conference
ACR 2019

Even though about half of the patients experienced a flare of their rheumatoid arthritis (RA), cancer therapy with immune checkpoint inhibitors (ICI) can be continued in most of the cases [1]. Results indicate that rates for serious immune-related adverse events are comparable to those for patients lacking autoimmune disease.

Having comorbidity of autoimmune disease generally leads to the exclusion of oncologic trials with ICI, as there are worries about more immune-related adverse events (irAEs) [1]. “However, patients with autoimmune diseases have the potential to benefit from the use of these therapies,” commented Dr Sabina Sandigursky (New York University Langone Medical Center, USA).

The reported study investigated 84 patients with known autoimmunity who had been treated with anti-CTLA-4 and PD-1 for their cancer from 2011-2018. There were 22 patients of this group who suffered from RA. The majority was female (73%), median age was 67. When sta...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on